09:49 EST GeneDx (WGS) ‘committing widespread fraud’ according to insiders, Grizzly says Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing ...

TD Cowen raised the firm’s price target on GeneDx (WGS) to $118 from $75 and keeps a Buy rating on the shares. The firm reviewed its financial model following the stock’s rise and believes ...

Initiating coverage on GeneDX Holdings Corp. ahead of Q4 and Full-Year 2024 earnings, releasing pre-market on February 18th. GeneDX specializes in genetic testing and personalized health plans for ...

A little-known stock started to make a huge name for itself in 2024. That stock is GeneDX WGS. Through the course of 2024, this healthcare company increased its market capitalization from under $ ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set ...